Close Menu

synthetic genomics

Wall Street analysts are bullish on the firm's cell selection platform technology, which could find a total addressable market of more than $20 billion.

The Bay Area DNA synthesis company said it was "not significantly affected" by the COVID-19 pandemic and beat Wall Street revenue estimates.

The firm is offering approximately 3 million shares and said it may use a portion of the proceeds to acquire, license, or invest in complementary businesses or products.

Single-cell analysis, next-generation sequencing, and synthetic DNA have all been crucial to efforts to find antibodies that could neutralize SARS-CoV-2.

Silicon Valley venture capital firm Andreessen Horowitz led the round, joined by 8VC, SV Angel, Allen & Co, and several other undisclosed private investors.

The synthetic biology firm had total revenues of $19.3 million and withdrew its financial guidance for fiscal year 2020 citing uncertainty caused by COVID-19.

In Nature this week: method to cluster cells based on single-cell RNA sequencing reads, synthetic genomics platform reconstructs SARS-CoV-2, and more.

The researchers used a yeast-based synthetic genomics platform to engineer and resurrect chemically synthesized clones of the SARS-CoV-2 virus in only a week.

On a conference call to discuss the firm's fiscal Q1 financial results, Twist executives detailed the firm's vision for near- and long-term growth.

A hearing scheduled for Friday, part of a lawsuit filed by Agilent was cancelled, leading to speculation the sides were close to a settlement.

Pages

The head of Operation Warp Speed tells Bloomberg he expects the paused AstraZeneca and Johnson & Johnson vaccine trials to resume soon.

A new UK government says socioeconomic factors, not genetics, account for disparities in deaths due to COVID-19 between ethnic groups, the Financial Times reports.

NPR reports on an Alzheimer's disease drug trial that is continuing despite the pandemic.

In Nature this week: CRISPR-Cas3 system for making large deletions efficiently, more.